IceCure Medical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Market Cap


About IceCure Medical

IceCure Medical develops minimally invasive products for the treatment of breast tumors and other internal diseased tissue. The company focuses on benign (non-cancerous) tumors, especially fibroadenoma in the women's health space. Treatment is based on disruptive cryosurgery technology, which is reliable and safe and saves surgical, hospitalization, recovery and rehabilitation costs.

IceCure Medical Headquarters Location

7 Haeshel St.

Caesarea, 38900,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing IceCure Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IceCure Medical is included in 5 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,471 items

Startups focused on providing products and services catering to women's health and wellbeing.


Medical Devices

11,738 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,900 items

IceCure Medical Patents

IceCure Medical has filed 16 patents.

The 3 most popular patent topics include:

  • Cryogenics
  • Flow meters
  • Fluid dynamics
patents chart

Application Date

Grant Date


Related Topics




Cryogenics, Cooling technology, Heat exchangers, Phase transitions, Industrial gases


Application Date


Grant Date



Related Topics

Cryogenics, Cooling technology, Heat exchangers, Phase transitions, Industrial gases



Latest IceCure Medical News

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

May 11, 2022

USA - English Share this article Share this article CAESAREA, Israel, May 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM ) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced it will report its business and financial results for the first quarter ended March 31, 2022 on Wednesday, May 18, 2022 with a press release issued at 7:00 am ET. IceCure's management team, joined by Dr. Richard Fine, will host a conference call that morning at 8:30 am ET. Dr. Richard E. Fine, MD, past President of the American Society of Breast Surgeons, an ICE3 trial investigator, Program Director of the Breast Surgical Oncology Fellowship, and Director of Research and Education at the West Comprehensive Breast Center in Germantown, Tennessee, will be on the call to discuss ProSense® as a potential treatment for early stage breast cancer and will be available for Q&A with investors. Conference call: US: 1-888-281-1167  About IceCure Medical Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM ) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark. Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses the scheduling of a conference call and reporting its business and financial results for first quarter ended March 31, 2022. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC's website, . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. IR Contact:

IceCure Medical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

IceCure Medical Rank

  • Where is IceCure Medical's headquarters?

    IceCure Medical's headquarters is located at 7 Haeshel St., Caesarea.

  • What is IceCure Medical's latest funding round?

    IceCure Medical's latest funding round is PIPE.

  • Who are the investors of IceCure Medical?

    Investors of IceCure Medical include Rosario Underwriting Services, Reut Alfia, Apax Partners, Yair Capital, Yaron Iluz and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.